819 related articles for article (PubMed ID: 19479202)
1. Dendritic cell-based cancer immunotherapies.
Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
[TBL] [Abstract][Full Text] [Related]
2. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
Sun K; Wang L; Zhang Y
Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells and their role in cancer immunotherapy.
Jalili A
Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
[TBL] [Abstract][Full Text] [Related]
6. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
7. The use of dendritic cells in cancer immunotherapy.
Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
[TBL] [Abstract][Full Text] [Related]
8. Appropriate timing of CD40 ligation for RNA-Pulsed DCs to induce antitumor immunity.
Miura S; Kagamu H; Tanaka H; Yoshizawa H; Gejyo F
Scand J Immunol; 2008 Apr; 67(4):385-91. PubMed ID: 18282232
[TBL] [Abstract][Full Text] [Related]
9. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
Tacken PJ; de Vries IJ; Torensma R; Figdor CG
Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
[TBL] [Abstract][Full Text] [Related]
10. IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
Santini SM; Lapenta C; Santodonato L; D'Agostino G; Belardelli F; Ferrantini M
Handb Exp Pharmacol; 2009; (188):295-317. PubMed ID: 19031032
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines for established cancer: how to make them better?
Andrews DM; Maraskovsky E; Smyth MJ
Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
[TBL] [Abstract][Full Text] [Related]
12. The 'kiss of death' by dendritic cells to cancer cells.
Chan CW; Housseau F
Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells: emerging roles in tumor immunotherapy.
Buchsel PC; DeMeyer ES
Clin J Oncol Nurs; 2006 Oct; 10(5):629-40. PubMed ID: 17063617
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-based immunotherapy.
Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
[TBL] [Abstract][Full Text] [Related]
15. The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity.
Houtenbos I; Santegoets S; Westers TM; Waisfisz Q; Kipriyanov S; Denkers F; Scheper RJ; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2008 Jun; 142(2):273-83. PubMed ID: 18492117
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells: limited potential in immunotherapy.
Soruri A; Zwirner J
Int J Biochem Cell Biol; 2005 Feb; 37(2):241-5. PubMed ID: 15474968
[TBL] [Abstract][Full Text] [Related]
17. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells as vectors for immunotherapy of cancer.
Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK
Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163
[TBL] [Abstract][Full Text] [Related]
19. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
